Medical Conference Schedule Sept. 2013 through March 2014

Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough
Source: Streetwise Reports (10/02/2025)

Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.

read more >

Biotech Battles FDA, Target Price Shows Potential 90% Gains
Source: Dr. Boobalan Pachaiyappan (10/01/2025)

Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy.

read more >

Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy
Source: Streetwise Reports (10/01/2025)

Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.

read more >

Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Source: Brian Abrahams (09/29/2025)

Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development.

read more >

Biotech Discovers Breakthrough DMD Therapy Opportunity
Source: Dr. Leland Gershell (09/26/2025)

Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc.

read more >